PAHC — Phibro Animal Health Corporation stock price, charts and financials

QT50Phibro Animal Health Corporation

Phibro Animal Health Corporation (NASDAQ: PAHC) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
37.15
+0.82+2.26%
PAHCQT50Phibro Animal Health Corporation·NASDAQ
37.15+2.26%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E15.53EPS (ttm)2.34Insider Own-Shs Outstand40.54MPerf Week6.76%
Market Cap1.47BForward P/E9.86EPS next Y3.68Insider Trans-0.90%Shs Float40.24MPerf Month13.18%
Enterprise Value2.21BPEG0.08EPS next Q0.72Inst Own-Short Float3.03%Perf Quarter-31.68%
Income95.14MP/S0.98EPS this Y43.50%Inst Trans-Short Ratio3.35Perf Half Y-8.92%
Sales1.50BP/B4.07EPS next Y10.20%ROA6.59%Short Interest1.22MPerf YTD-2.76%
Book/sh-P/C22.28EPS next 5Y13.04%ROE29.49%52W High61.44 -39.53%Perf Year30.12%
Cash/sh-P/FCF115.32EPS past 3/5Y-0.55% 7.47%ROIC11.38%52W Low26.16 42.03%Perf 3Y145.81%
Dividend Est.0.48 (1.29%)EV/EBITDA9.79Sales past 3/5Y11.22% 10.13%Gross Margin32.49%Volatility3.87% 3.91%Perf 5Y49.44%
Dividend TTM0.48 (1.29%)EV/Sales1.47EPS Y/Y TTM3783.33%Oper. Margin12.27%ATR (14)1.40Perf 10Y78.79%
Dividend Ex-DateSep 02, 2026Quick Ratio1.26Sales Y/Y TTM47.45%Profit Margin6.35%RSI (14)62.53Recom2.86
Dividend Gr. 3/5Y0.00% 0.00%Current Ratio3.17EPS Q/Q61.11%SMA206.56%Beta0.46Target Price49.00
Payout20.43%Debt/Eq2.18Sales Q/Q10.34%SMA5010.93%Rel Volume0.58Prev Close36.33
Employees2,475LT Debt/Eq2.57EarningsAug 26SMA200-14.77%Avg Volume356.44KPrice37.15
IPO DateApr 11, 2014Option/ShortYes / YesEPS/Sales Surpr.29.85% 5.14%Net Debt/EBITDA3.25Volume205,472Change2.26%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-06-26ReiteratedMorgan StanleyEqual Weight$45$49
Aug-28-25ReiteratedMorgan StanleyEqual Weight$26$34
Jul-07-25UpgradeJP MorganNeutralOverweight
Jun-25-25ReiteratedMorgan StanleyEqual Weight$20$26
Apr-15-25ReiteratedMorgan StanleyEqual Weight$27$20
Dec-21-22ReiteratedRoth CapitalBuy$18
Sep-16-22ReiteratedBarclaysUnderweight$17
Aug-26-22ReiteratedMorgan StanleyEqual Weight$21
Jul-25-22DowngradeBarclaysEqual WeightUnderweight
Jan-10-22UpgradeBarclaysUnderweightEqual Weight
Latest News
Jul-28-26
Jul-27-26
Jul-15-26
Jul-14-26
Jul-09-26
Jul-06-26
Jun-29-26
Jun-26-26
Jun-19-26
Company

Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
6/30/2025
FY 2024
6/30/2024
FY 2023
6/30/2023
FY 2022
6/30/2022
FY 2021
6/30/2021
FY 2020
6/30/2020
FY 2019
6/30/2019
FY 2018
6/30/2018
Total Revenue1,5011,2961,018978942833800828820
Cost of Goods Sold Incl. D&A1,012896705680657562543563553
Gross Profit488400313298285271257265267
Selling, General and Administrative Excl. Other302289260226206197188181168
Research and Development00000001210
Other Operating Expense0000000-12-10
Operating Income18411053727975697399
Interest Expense453322181210141414
Unusual Expense
Non-Operating Income (Expense)-9-9-200521123
Net Income Before Taxes1286811547266567288
Income Taxes34209212312221723
Consolidated Net Income95482334954345565
Net Income From Continuing Operations95482334954345565
Net Income95482334954345565
EPS (Recurring)2.341.190.060.811.211.340.831.351.61
EPS (Basic, Before Extraordinaries)2.341.190.060.811.211.340.831.351.61
EPS (Diluted)2.331.190.060.811.211.340.831.351.61
EBITDA22614769106117110102113129
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio15.9421.46279.5016.9115.8121.5531.6523.5328.60
Price To Sales Ratio1.010.810.680.570.831.421.351.532.25
Gross Margin32.5130.8630.7530.4730.2532.5332.1332.0032.56
Operating Margin12.268.495.217.368.399.008.638.8212.07
Net Margin6.333.700.203.375.206.484.256.647.93
Shares Outstanding414141414141414040
Market Capitalization1,5231,0476885627841,1841,0771,2711,842
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$65.06$53.18$41.30$29.42$17.54 Close Price0.00M3.05M6.10M9.14M12.19MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
CORCORAN E THOMASDirectorMay 29 '26Buy31.7710,000317,70041,459Jun 02
BENDHEIM JACKPresident and CEOMay 07 '26Sale48.494,528219,56856,152May 07
BENDHEIM JACKPresident and CEOMay 06 '26Sale57.377,040403,85060,680May 07
BENDHEIM JACKPresident and CEOMay 05 '26Sale55.807,040392,81067,720May 07
BENDHEIM JACKPresident and CEOApr 30 '26Sale52.767,040371,46674,760Apr 30
BENDHEIM JACKPresident and CEOApr 29 '26Sale52.927,040372,55281,800Apr 30
BENDHEIM JACKPresident and CEOApr 28 '26Sale55.917,040393,57688,840Apr 30
BENDHEIM JACKPresident and CEOApr 23 '26Sale54.097,040380,82695,880Apr 23
BENDHEIM JACKPresident and CEOApr 22 '26Sale54.297,040382,185102,920Apr 23
BENDHEIM JACKPresident and CEOApr 21 '26Sale55.987,040394,081109,960Apr 23
BENDHEIM JACKPresident and CEOApr 16 '26Sale54.647,040384,661117,000Apr 16
BENDHEIM JACKPresident and CEOApr 15 '26Sale56.967,040401,01124,040Apr 16
BENDHEIM JACKPresident and CEOApr 14 '26Sale59.087,040415,92231,080Apr 16
BENDHEIM JACKPresident and CEOMar 31 '26Sale53.907,040379,42838,120Mar 31
BENDHEIM JACKPresident and CEOMar 30 '26Sale53.617,040377,40645,160Mar 31
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.